2026 DF PEPTIDE ACQUISITION LLC – Trademark Portfolio
Entity Type: 16
2026 DF PEPTIDE ACQUISITION LLC holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 6 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ENCODIA and PROTEOCODE. The owner is based in NEW YORK, NY.
345 PARK AVENUE SOUTH
NEW YORK, NY 10010
Showing of trademarks Trademarks
Trademark Classifications
2026 DF PEPTIDE ACQUISITION LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does 2026 DF PEPTIDE ACQUISITION LLC have?
2026 DF PEPTIDE ACQUISITION LLC has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 abandoned.
What trademark classes does 2026 DF PEPTIDE ACQUISITION LLC file in?
2026 DF PEPTIDE ACQUISITION LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 1 (Chemicals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are 2026 DF PEPTIDE ACQUISITION LLC's most well-known trademarks?
2026 DF PEPTIDE ACQUISITION LLC's registered trademark portfolio includes well-known marks such as ENCODIA and PROTEOCODE. These are among 2 currently registered trademarks in the portfolio.
What is 2026 DF PEPTIDE ACQUISITION LLC's trademark registration success rate?
2026 DF PEPTIDE ACQUISITION LLC has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.